Search Results - "Sayed, Christopher J."

Concomitance of Hidradenitis Suppurativa and Porokeratoses.

Authors: SAYED, CHRISTOPHER J. EL-BEHAEDI, SALMA E. OSBORN, LINDSAY P. et al.

Source: Journal of Clinical & Aesthetic Dermatology. Apr2023, Vol. 16 Issue 4, p28-31. 4p.

An evolutionary tale on clinical trials in hidradenitis suppurativa.

Authors: Sayed, Christopher J Shams, Rayad B Midgette, Bria et al.

Source: British Journal of Dermatology. 2025 Supplement, Vol. 192, pi15-i21. 7p.

Nonmalignant Dermatologic Disorders in Inflammatory Bowel Disease.

Authors: Isaacs, Kim L. Sayed, Christopher J.

Source: American Journal of Gastroenterology (Lippincott Williams & Wilkins). Jan2025, Vol. 120 Issue 1, p115-124. 10p.

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.

Authors: Kimball, Alexa B Jemec, Gregor B E Sayed, Christopher J et al.

Source: Lancet. Jun2024, Vol. 403 Issue 10443, p2504-2519. 16p.

Subjects: UCB SA, Hidradenitis suppurativa, Clinical trials, Thrush (Mouth disease), Patient safety, Heart failure patients, Congestive heart failure, Coronavirus diseases

Defining Moderate Disease and Progression in Hidradenitis Suppurativa: An Expert Framework to Unlock the Window of Opportunity for Prompt Treatment.

Authors: Martorell, Antonio Ingram, John R. Sayed, Christopher J. et al.

Source: American Journal of Clinical Dermatology. Mar2026, Vol. 27 Issue 2, p217-226. 10p.

Criteria for Hidradenitis Suppurativa Competence Centers.

Authors: Marzano, Angelo V. Bechara, Falk G. Shi, Vivian Y. et al.

Source: Dermatology & Therapy. Jul2026, Vol. 16 Issue 7, p3445-3460. 16p.

Clinical Epidemiology and Management of Hidradenitis Suppurativa.

Authors: Sayed, Christopher J. Hsiao, Jennifer L. Okun, Martin M. et al.

Source: Obstetrics & Gynecology. Apr2021, Vol. 137 Issue 4, p731-746. 16p.

Dual Targeted Therapy for Hidradenitis Suppurativa: A Narrative Review.

Authors: Kherallah, Kenan Chung, Claire S. Ghanshani, Raveena et al.

Source: Dermatology & Therapy. Jan2026, Vol. 16 Issue 1, p231-245. 15p.

Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials.

Authors: Ingram, John R. Fujita, Hideki Gottlieb, Alice B. et al.

Source: Pain & Therapy. Dec2025, Vol. 14 Issue 6, p1861-1878. 18p.

Dermatologist perceptions and preferences of laser hair reduction for hidradenitis suppurativa.

Authors: Mallela, Teja Wadhera, Akhil Sayed, Christopher J.

Source: Archives of Dermatological Research. 7/12/2025, Vol. 317 Issue 1, p1-5. 5p.

The Successful Use of Upadacitinib as Monotherapy for Hidradenitis Suppurativa and Ulcerative Colitis in the Setting of Refractory Disease.

Authors: Ok, Meryem T. Googe, Paul B. Sayed, Christopher J. et al.

Source: Pediatric Dermatology. Mar2025, Vol. 42 Issue 2, p353-357. 5p.

PD‐L1 and LAG‐3 expression in advanced cutaneous squamous cell carcinomas.

Authors: Wu, Sam Slater, Nathaniel A. Sayed, Christopher J. et al.

Source: Journal of Cutaneous Pathology. Oct2020, Vol. 47 Issue 10, p882-887. 6p. 2 Color Photographs, 4 Charts.

Trends in Surgical Management of Hidradenitis Suppurativa.

Authors: Wendland, Zachary Jiang, Ziou Sayed, Christopher J. et al.

Source: Dermatologic Surgery. Apr2025, Vol. 51 Issue 4, p450-452. 3p.

International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab.

Authors: Zouboulis, Christos C. Prens, Errol P. Sayed, Christopher J. et al.

Source: Journal of the European Academy of Dermatology & Venereology. Jun2024, Vol. 38 Issue 6, pe496-e499. 4p.

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II.

Authors: Tzellos, Thrasyvoulos Giamarellos‐Bourboulis, Evangelos J. Straalen, Kelsey R. et al.

Source: Journal of the European Academy of Dermatology & Venereology. Feb2026, p1. 10p. 5 Illustrations.

Safety and efficacy of biologics in patients with Down syndrome and hidradenitis suppurativa: a retrospective cohort study.

Authors: Westerkam, Linnea L Santiago-Soltero, Karla Charrow, Alexandra et al.

Source: Clinical & Experimental Dermatology. Jul2025, Vol. 50 Issue 7, p1431-1433. 3p.

Understanding the real-world patient journey and unmet needs of people with hidradenitis suppurativa through social media research.

Authors: Kirby, Joslyn S Martorell, Antonio Sayed, Christopher J et al.

Source: British Journal of Dermatology. Aug2023, Vol. 189 Issue 2, p228-230. 3p.

Effect of Biologics on the Need for Procedural Interventions, Systemic Medications, and Healthcare Utilization in Patients with Hidradenitis Suppurativa: Real-World Data from the UNITE Registry.

Authors: Oliveira, Marília Rahawi, Kassim Duan, Yinghui et al.

Source: Dermatology & Therapy. Jul2023, Vol. 13 Issue 7, p1577-1585. 9p.

Readability of online materials for hidradenitis suppurativa.

Authors: Sluder, Isaac T. Stokes, Madison M. Sayed, Christopher J. et al.

Source: International Journal of Dermatology. Feb2023, Vol. 62 Issue 2, pe75-e77. 3p.

A Hidradenitis Suppurativa molecular disease signature derived from patient samples by high-throughput RNA sequencing and re-analysis of previously reported transcriptomic data sets.

Authors: Freudenberg, Johannes M. Liu, Zhi Singh, Jennifer et al.

Source: PLoS ONE. 4/6/2023, Vol. 18 Issue 4, p1-15. 15p.